Fractionated-dose radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody (epratuzumab).: Interim results.

被引：0
|
作者：
Chatal, JF
Harousseau, JL
Truemper, LH
Meller, J
Pfreundschuh, M
Kirsch, CM
Naumann, R
Kropp, J
Wegener, WA
Ding, C
Horak, ID
Goldenberg, DM
机构：
[1] Inst Biol, INSERM, Res Unit 4, Nantes, France
[2] Ctr Hosp Univ, Serv Hematol, Nantes, France
[3] Univ Gottingen, D-3400 Gottingen, Germany
[4] Univ Saarland, Sch Med, Hamburg, Germany
[5] Univ Hosp Dresden, Dresden, Germany
[6] Immunomed Inc, Morris Plains, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1482
引用
收藏
页码：408A / 408A
页数：1
相关论文
共 50 条
  • [1] Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of dota-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
    Chatal, JF
    Harousseau, JL
    Trümper, LH
    Meller, J
    Pfreundschuh, M
    Kirsch, CM
    Naumann, R
    Kropp, J
    Lateiner, JE
    Wegener, WA
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (04) : 525 - 526
  • [2] Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
    Lindén, O
    Hindorf, C
    Ståhl, EC
    Wegener, WA
    Goldenberg, DM
    Horne, H
    Ohlsson, T
    Stenberg, L
    Strand, SE
    Tennvall, J
    CLINICAL CANCER RESEARCH, 2005, 11 (14) : 5215 - 5222
  • [3] Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Chatal, JF
    Harousseau, JL
    Griesinger, F
    Meller, J
    Renner, C
    Kirsch, CM
    Naumann, R
    Kropp, J
    Wegener, WA
    Goldenberg, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 174S - 174S
  • [4] Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y
    Kraeber-Bodere, F.
    Morschhauser, F.
    Huglo, D.
    Petillon, M.
    Chatal, J.
    Harousseau, J. L.
    Horne, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Radioimmunotherapy in NHL at high cumulative doses of 90Y with fractionated doses of dota-conjugated, humanized anti-CD22 IGG, epratuzumab
    Morschhauser, F.
    Kraeber-Bodere, F.
    Huglo, D.
    Petillon, M.
    Chatal, J.
    Harousseau, J.
    Home, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 88 - 88
  • [6] Fractionated radioimmunotherapy in NHL with dota-conjugated, humanized anti-CD22 epratuzumabat high cumulative 90Y doses
    Morschhauser, F.
    Kraeber-Bodere, F.
    Petillon, M.-O.
    Chatal, J.-F.
    Harousseau, J.-L.
    Horne, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 151 - 151
  • [7] Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): Phase I/II trial results.
    Leonard, JP
    Coleman, M
    Schuster, MW
    Chadburn, A
    Ely, S
    Yagan, N
    Sharkey, RM
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 1999, 94 (10) : 92A - 93A
  • [8] Interim results of a phase I/II radioimmunotherapy trial in relapsed/refractory non-Hodgkin's lymphoma (NHL) patients given 90Y-labeled anti-CD22 humanized monoclonal antibody, epratuzumab.
    Hajjar, G
    Sharkey, RM
    Burton, J
    Schuster, S
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, EA
    Leonard, J
    Coleman, M
    Plutchock, J
    Brenner, AI
    Goldenberg, DM
    BLOOD, 2001, 98 (11) : 611A - 611A
  • [9] Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Matthews, JC
    Chadburn, A
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Kapushoc, H
    Gayko, U
    Cesano, A
    Fields, SZ
    Goldenberg, DM
    BLOOD, 2002, 100 (11) : 358A - 358A
  • [10] Clinical update on fractionated radioimmunotherapy in patients with NHL using humanized 90Y labeled anti-CD22 epratuzumab
    Chatal, J
    Harousseau, J
    Griesinger, F
    Meller, J
    Pfreundschuh, M
    Kirsch, C
    Naumann, R
    Kropp, J
    Morschhauser, F
    Huglo, D
    ANNALS OF ONCOLOGY, 2005, 16 : 68 - 69
12345